Cardioprotection
Study results from K. Chatterjee and colleagues in the area of cardioprotection published
Published in Cardiovascular Device Liability Week, December 30th, 2007
"We hypothesized that vincristine, which disrupts microtubules, should have the opposite effect. To our surprise, we found that pretreatment with concentrations of vincristine ranging from 30 to 120 mu mol/L for 60 min preserved myocyte viability and morphology after incubation with 30 mu mol/L of H2O2 for 35 min as measured by trypan blue exclusion. The cardioprotective effects of vincristine were also...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cardiovascular Device Liability Week
More Articles from Cardiovascular Device Liability Week
- Heart Attack
Congress Clears the Way for National CPR and AED Awareness Week - Abdominal Aortic Aneurysm
Research from Russells Hall Hospital broadens understanding of abdominal aortic aneurysm - Abdominal Aortic Aneurysm
Study findings from University of Chicago, Department of Surgery broaden understanding of abdominal aortic aneurysm - Acute Leukemia
Researchers at Charles University target acute leukemia - Acute Myelogenous Leukemia
Vion Pharmaceuticals Presents Preliminary Data from its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Acute Myelogenous Leukemia at ASH Annual Meeting - Aging
Data on aging published by R.C. Becker and colleagues - More from this issue of Cardiovascular Device Liability Week
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
